These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 25644760

  • 1. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome.
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
    Nanda A, Reddy R, Safraz H, Salameh H, Singal AK.
    J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
    [Abstract] [Full Text] [Related]

  • 3. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA, Huang X, Jamil K, Corman S, Ektare V, Niewoehner J.
    J Med Econ; 2023 Jun; 26(1):1342-1348. PubMed ID: 37729445
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
    Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S.
    Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 7. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
    Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P.
    Hepatology; 2016 Mar; 63(3):983-92. PubMed ID: 26659927
    [Abstract] [Full Text] [Related]

  • 8. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL.
    Cochrane Database Syst Rev; 2017 Sep 27; 9(9):CD011532. PubMed ID: 28953318
    [Abstract] [Full Text] [Related]

  • 9. The Treatment of Hepatorenal Syndrome.
    Cavallin M, Fasolato S, Marenco S, Piano S, Tonon M, Angeli P.
    Dig Dis; 2015 Sep 27; 33(4):548-54. PubMed ID: 26159272
    [Abstract] [Full Text] [Related]

  • 10. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.
    Aliment Pharmacol Ther; 2017 Jun 27; 45(11):1390-1402. PubMed ID: 28370090
    [Abstract] [Full Text] [Related]

  • 11. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
    Flamm SL, Wong F, Ahn J, Kamath PS.
    Clin Gastroenterol Hepatol; 2022 Dec 27; 20(12):2707-2716. PubMed ID: 36075500
    [Abstract] [Full Text] [Related]

  • 12. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug 27; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 13. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 2002 Oct 27; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [Abstract] [Full Text] [Related]

  • 14. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M, Götz E, Scholz-Kreisel P, Ahrens J, Sivanathan V, Schattenberg J, Rey JW, Wörns MA, Galle PR, Marquardt JU.
    Dtsch Med Wochenschr; 2015 Jan 27; 140(2):e21-6. PubMed ID: 25612289
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.
    Reddy KR, Weinberg EM, Gonzalez SA, Izzy MJ, Simonetto DA, Frederick RT, Rubin RA, Fricker Z, Ikahihifo-Bender J, Harte M, Garcia S, Campbell K, Olofson A, Razavi RF, James JM, Patel H, Kim-Lee G, Witkiewicz S, Tobin W, Jamil K.
    Liver Transpl; 2024 Oct 01; 30(10):1026-1038. PubMed ID: 38771635
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.
    Hepatogastroenterology; 2003 Dec 01; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [Abstract] [Full Text] [Related]

  • 17. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
    Gonzalez SA, Chirikov VV, Wang WJ, Huang X, Jamil K, Simonetto DA.
    Clin Transl Gastroenterol; 2023 Dec 01; 14(12):e00627. PubMed ID: 37622521
    [Abstract] [Full Text] [Related]

  • 18. Evidence-Based Therapeutic Options for Hepatorenal Syndrome.
    Glass L, Sharma P.
    Gastroenterology; 2016 Apr 01; 150(4):1031-3. PubMed ID: 26922867
    [No Abstract] [Full Text] [Related]

  • 19. Hepatorenal syndrome: The last pieces of the puzzle or not yet?
    Graupera I, Ginès P.
    Hepatology; 2015 Aug 01; 62(2):352-4. PubMed ID: 25846649
    [No Abstract] [Full Text] [Related]

  • 20. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.
    Ann Hepatol; 2009 Aug 01; 8(3):207-11. PubMed ID: 19841499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.